HGH Fragment 176-191
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
HGH Fragment 176-191 is the bare lipolytic fragment of human growth hormone — the same residue region AOD-9604 is built from, but without the disulfide-bond / tyrosine modification that stabilizes AOD. Per the 0035 pass: “Same molecule body as AOD-9604 (without disulfide bond).” thepeptidelist.com files it under weight-loss.
Both compounds are part of the same fat-loss-peptide story: HGH itself has a fat-metabolizing portion and a growth-promoting portion, and both AOD-9604 and this bare fragment were isolated to try to capture the fat-burning slice without the rest of the hormone’s effects. The difference between the two is stabilization — and, critically, evidence depth.
What does it do in my body?
Per thepeptidelist.com: an isolated lipolytic region of HGH that may stimulate fat breakdown without affecting blood sugar or promoting cellular growth.
Mechanistically it’s marketed identically to AOD-9604 — the fat-burning slice of growth hormone, GH effects stripped out. The difference is stabilization and, critically, evidence depth.
How can it help me?
- Where the science stands: Thinnest in the metabolic-peptide cluster — 1 study cited, 0 human trials, and that one study isn’t about fat loss
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
No specific adverse-event signal is documented for this compound in the source material. Because it shares AOD-9604’s mechanism (fat-loss region of HGH stripped of growth and blood-sugar effects), it’s assumed by analogy to carry a similarly benign profile — but that assumption has no independent human safety data behind it, since the only formal study on record is an unrelated in-vitro cancer-cell paper. Treat any safety claim about this specific compound as inferred, not established.
Regulatory status: research_only — not approved for human use, not eligible for compounding (per thepeptidelist.com). OHM grade: D / provisional (kept provisional, encyclopedia-only). Not in Alyve’s launch catalog of 15 SKUs.
Typical dosing
Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.
No validated protocol exists. The community treats it interchangeably with AOD-9604 (similar mcg-range subcutaneous, fasted-AM convention), but there is no human dose-finding study and no captured cheat-sheet row for this exact compound.
What should I avoid combining — and what's synergistic?
HGH Fragment 176-191 doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
How can I buy this?
We don't have a verified affiliate source for HGH Fragment 176-191 yet, so there's no coupon or vendor link here — we won't point you to a seller we haven't vetted. When buying any research-use-only peptide, the single biggest variable is the supply chain: insist on a vendor that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity. Working with a peptide-literate clinician is one solid route — see our provider directory — or check back as our verified sources list grows.
The bare, unstabilized version of the same growth-hormone fragment behind AOD-9604 — same fat-burning theory, thinner evidence, and the thinnest formal data trail in the metabolic-peptide space.
| Class | Bare C-terminal fragment of human growth hormone (amino acids 176-191), same residue region as AOD-9604 but without the disulfide-bond / tyrosine stabilization |
| Mechanism (one line) | Claimed to stimulate fat breakdown from the same lipolytic HGH region, without affecting blood sugar or promoting cellular growth |
| Evidence base | Thinnest in the metabolic-peptide cluster — 1 study cited, 0 human trials, and that one study isn’t about fat loss |
| Safety record | No specific adverse-event signal documented; inherits AOD-9604’s benign no-GH-axis profile by molecular analogy, but with no independent human safety data of its own |
| Regulatory status | research_only; not FDA-approved; not eligible for compounding |
What it is
HGH Fragment 176-191 is the bare lipolytic fragment of human growth hormone — the same residue region AOD-9604 is built from, but without the disulfide-bond / tyrosine modification that stabilizes AOD. Per the 0035 pass: “Same molecule body as AOD-9604 (without disulfide bond).” thepeptidelist.com files it under weight-loss.
Both compounds are part of the same fat-loss-peptide story: HGH itself has a fat-metabolizing portion and a growth-promoting portion, and both AOD-9604 and this bare fragment were isolated to try to capture the fat-burning slice without the rest of the hormone’s effects. The difference between the two is stabilization — and, critically, evidence depth.
How it works
Per thepeptidelist.com: an isolated lipolytic region of HGH that may stimulate fat breakdown without affecting blood sugar or promoting cellular growth.
Mechanistically it’s marketed identically to AOD-9604 — the fat-burning slice of growth hormone, GH effects stripped out. The difference is stabilization and, critically, evidence depth.
What the research shows
This is the thinnest evidence base in the metabolic-peptide cluster:
- thepeptidelist.com grades it Anecdotal — 1 study cited, 0 human trials.
- The single cited study isn’t even about fat loss: it’s an in-vitro breast-cancer paper — the fragment enhanced the cytotoxicity of doxorubicin-loaded chitosan nanoparticles against MCF-7 cells (Habibullah et al., Drug Des Devel Ther 2022, PMID 35783198). That tells us nothing about human fat loss.
- OHM grade: D / provisional — “Same negative-Ph2 lineage; no independent grounding.” It inherits AOD-9604’s failed-Phase-2 story without adding any human data of its own.
The honest read: HGH Fragment 176-191 is researcher-community interest with formal data that is thin. It rides on the same GH-fragment fat-loss premise as AOD-9604 — and that premise has a negative human Phase 2 behind it. Educational mention; no recommendation.
Real-world protocol
The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice.
No validated protocol exists. The community treats it interchangeably with AOD-9604 (similar mcg-range subcutaneous, fasted-AM convention), but there is no human dose-finding study and no captured cheat-sheet row for this exact compound.
Side effects & management
No specific adverse-event signal is documented for this compound in the source material. Because it shares AOD-9604’s mechanism (fat-loss region of HGH stripped of growth and blood-sugar effects), it’s assumed by analogy to carry a similarly benign profile — but that assumption has no independent human safety data behind it, since the only formal study on record is an unrelated in-vitro cancer-cell paper. Treat any safety claim about this specific compound as inferred, not established.
Regulatory status
research_only — not approved for human use, not eligible for compounding (per thepeptidelist.com). OHM grade: D / provisional (kept provisional, encyclopedia-only). Not in Alyve’s launch catalog of 15 SKUs.
Sources
- thepeptidelist.com directory profile; primary source for mechanism, evidence tier, and regulatory status (all site-derived citations carry per KB doctrine).
- OHM tier/safety grading (D/provisional; “same negative-Ph2 lineage; no independent grounding”).
- cited: 35783198 (Habibullah et al. 2022, Drug Des Devel Ther — in-vitro breast-cancer cytotoxicity model, not a fat-loss study).
Related: AOD-9604 · Retatrutide · Tesamorelin · MOTS-c · The GLP-1 Pipeline (2026).
Sources & references
- thepeptidelist.com directory profile; primary source for mechanism, evidence tier, and regulatory status (all site-derived citations carry per KB doctrine).
- OHM tier/safety grading (D/provisional; “same negative-Ph2 lineage; no independent grounding”).
- cited: 35783198 (Habibullah et al. 2022, Drug Des Devel Ther — in-vitro breast-cancer cytotoxicity model, not a fat-loss study).
Related: AOD-9604 · Retatrutide · Tesamorelin · MOTS-c · The GLP-1 Pipeline (2026).